Daratumumab (Darzalex®) in combination with lenalidomide and dexamethasone

Assessment Status Rapid review complete
HTA ID -
Drug Daratumumab in combination with lenalidomide and dexamethasone 
Brand Darzalex®
Indication For the treatment of adult patients with multiple myeloma wo have received at least one prior therapy.
Assessment Process
Rapid review commissioned 09/10/2017
Rapid review completed 27/11/2017
Rapid review outcome A full pharmacoeconomic evaluation is recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.